Author Question: Why did the use of intermittent positive-pressure breathing decline in the 1980s? a. Due to a ... (Read 18 times)

tth

  • Hero Member
  • *****
  • Posts: 579
Why did the use of intermittent positive-pressure breathing decline in the 1980s?
 
  a. Due to a lack of scientific evidence to support its use for delivering aerosolized medication
  b. Due to its cost of implementation
  c. Due to its complexity
  d. Replaced by newer technology

Question 2

All of the following are goals of noninvasive ventilation (NIV) in the acute care setting, except:
 
  a. avoid intubation.
  b. decrease incidence of ventila-tion-associated pneumonia.
  c. decrease length of stay.
  d. improve mobility.



bdobbins

  • Sr. Member
  • ****
  • Posts: 326
Answer to Question 1

ANS: A
The use of intermittent positive-pressure breathing declined significantly in the mid-1980s after a randomized, controlled trial revealed no benefit, compared to a simple small-volume nebulizer, in the treatment of patients with chronic obstructive pulmonary disease.

Answer to Question 2

ANS: D
Avoiding intubation and invasive positive-pressure ventilation, improving survival, decreasing the length of ventilatory support, decreasing the length of hospitalization, and decreasing the inci-dence of ventilator-associated pneumonia are major goals of NIV in the acute care setting (emer-gency department, intensive care unit, or hospital ward).



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question

tth

  • Hero Member
  • *****
  • Posts: 579

bdobbins

  • Sr. Member
  • ****
  • Posts: 326

 

Did you know?

All adverse reactions are commonly charted in red ink in the patient's record and usually are noted on the front of the chart. Failure to follow correct documentation procedures may result in malpractice lawsuits.

Did you know?

In 1835 it was discovered that a disease of silkworms known as muscardine could be transferred from one silkworm to another, and was caused by a fungus.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

Did you know?

Less than one of every three adults with high LDL cholesterol has the condition under control. Only 48.1% with the condition are being treated for it.

Did you know?

The first war in which wide-scale use of anesthetics occurred was the Civil War, and 80% of all wounds were in the extremities.

For a complete list of videos, visit our video library